Redefinition from NAFLD/NASH to MASLD/MASH
The American Association for the Study of Liver Disease (AASLD), the European Association for the Study of the Liver (EASL) and the Asociacion Latinoamericana para el Estudio del Higado (ALEH) have collaborated to present a statement on disease definitions, names and diagnostic methods for nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH).
Title: A multi-society Delphi consensus statement on new fatty liver disease nomenclature
( Rinella et al., J. Hepatol., 2023 )
Previously, the disease name NAFLD/NASH was used, but to accurately describe the etiology and symptoms, the disease name has been changed to metabolic dysfunction associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
We have previously introduced the STAM™ model as the NAFLD/NASH-HCC model, but we have started discussions with medical experts on the category based on the new definition.
We will announce the position of the STAM™ mouse in the new SLD shortly.
If you have any interest or questions, please feel free to contact us.